Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Silence Therapeutics (SLN) over the last 6 years, with Q3 2025 value amounting to 16505.66%.

  • Silence Therapeutics' EBITDA Margin fell 145509000.0% to 16505.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 321.21%, marking a year-over-year increase of 388900.0%. This contributed to the annual value of 146.38% for FY2024, which is 481900.0% up from last year.
  • As of Q3 2025, Silence Therapeutics' EBITDA Margin stood at 16505.66%, which was down 145509000.0% from 10697.77% recorded in Q2 2025.
  • Silence Therapeutics' EBITDA Margin's 5-year high stood at 0.0% during Q3 2021, with a 5-year trough of 20006.34% in Q1 2025.
  • Its 5-year average for EBITDA Margin is 2932.96%, with a median of 386.74% in 2022.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 6163900bps in 2024, then plummeted by -199727600bps in 2025.
  • Quarter analysis of 5 years shows Silence Therapeutics' EBITDA Margin stood at 329.91% in 2021, then soared by 30bps to 230.03% in 2022, then tumbled by -175bps to 633.59% in 2023, then skyrocketed by 97bps to 17.2% in 2024, then tumbled by -95873bps to 16505.66% in 2025.
  • Its EBITDA Margin was 16505.66% in Q3 2025, compared to 10697.77% in Q2 2025 and 20006.34% in Q1 2025.